The expansion to SGS’s Poitiers facility in France is expected to improve the company’s drug development capabilities.
SGS announced the completion of expansions to its bioanalytical laboratory in Poitiers, France on Sept. 30, 2021. The addition consists of a new 800 m² building that houses additional drug development equipment and extra office space.
Included in the expansion are chromatography and immunoassay laboratories that are intended to dramatically increase production capacity. Additional capacities such as mass spectrometry, immunoanalysis, and cell-based bioassays will be added to the site’s existing capabilities.
The facility also adds new digital tools, such as customer relationship management and configure, price, quote software for contracting and monitoring. A large sample storage combined with bar code systems allows for storage of up to 800,000 samples at a time.
“The expansion comes at an exciting time,” said Walid Elbast, SGS’s general manager in France, in a company press release. “It allows us to meet increased demand in the area and shorten processes for our pharmaceutical clients. For me, this is a testimony to the outstanding teamwork of everyone involved and SGS’s continued investment in supporting innovation in the life sciences sector.”
Source: SGS
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.